Cellebrite is successfully pivoting toward a high-margin, subscription-based digital intelligence model, evidenced by a robust 82.5% gross margin as of 2026Q1. While the company ha...
EPS beat 9 of last 12 quarters
P/E is 66% above its peer median
Laggard (Underperforming 61% of market)
Price < 200DMA
Estimated earnings - Aug 14
Trailing total returns as of 7/28/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Based on DCF analysis
Cellebrite DI Ltd. (CLBT) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $0.04vs $0.05-25.6% | $128Mvs $127M+1.0% |
| Q1 2026 | Feb 11, 2026 | $0.09vs $0.14-35.7% | $129Mvs $126M+2.1% |
| Q4 2025 | Nov 12, 2025 | $0.14vs $0.09+48.2% | $126Mvs $123M+2.5% |
| Q3 2025 | Aug 14, 2025 | $0.12vs $0.10+20.0% | $113Mvs $112M+1.0% |
Recent stock market news and headlines for Cellebrite DI Ltd. (CLBT)
/PRNewswire/ -- Cellebrite DI Ltd. (NASDAQ: CLBT), ein weltweit führender Anbieter von KI-gestützten Lösungen für digitale Ermittlungen und
TYSONS CORNER, Va. and PETAH TIKVA, Israel, July 21, 2026 /PRNewswire/ -- Cellebrite DI Ltd.
Hogan's non-discretionary sale satisfied tax withholding obligations from vesting RSUs. He retains 590,777 shares worth $9.25 million.
Key metrics vs top competitors for Cellebrite DI Ltd. (CLBT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $14.64 | $3.65B | 47.23 | 18.56% | 16.47% | 19.1% | — | |
| $525.48 | $42.34B | 348.00 | 33.47% | 6.91% | 6.58% | — | |
| $46.67 | $5.48B | -41.30 | 13.17% | -19.75% | -26.1% | — | |
| $15.15 | $567.62M | 7.97 | 0% | 28.47% | 27.31% | — | |
| $39.98 | $2.86B | 30.75 | 4.47% | 11.12% | 5.96% | — | |
| $20.67 | $456.69M | 36.91 | -7.29% | 8.26% | 3.67% | — |
Cellebrite DI Ltd. (CLBT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when CLBT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Cellebrite DI Ltd. (CLBT) stock FAQ — growth, dividends, profitability & financials explained
Cellebrite DI Ltd. (CLBT) reported $496.4M in revenue for fiscal year 2025. This represents a 189% increase from $171.9M in 2019.
Cellebrite DI Ltd. (CLBT) grew revenue by 18.6% over the past year. This is strong growth.
Yes, Cellebrite DI Ltd. (CLBT) is profitable, generating $71.9M in net income for fiscal year 2025 (16.5% net margin).
Cellebrite DI Ltd. (CLBT) has a return on equity (ROE) of 19.1%. This is reasonable for most industries.
Cellebrite DI Ltd. (CLBT) generated $154.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
